SCOHIA reported animal findings for CT-G32/SCO-940 on November 4, 2026. The four-pathway obesity candidate has a planned US development step, but no human comparison with retatrutide in this report. 1

What are the four pathways?

SCOHIA identifies GLP-1, GIP, glucagon and amylin as the four targets. Retatrutide’s original discovery paper describes activity at the first three. The additional amylin pathway is the main mechanistic distinction in this comparison, but counting targets cannot establish clinical benefit. 1 2

The retatrutide discovery work combined receptor experiments, animal studies and early human observations. It illustrates the different kinds of evidence needed to connect a molecular design with an effect in people. An attractive mechanism is a research rationale; it does not settle comparative efficacy or safety. 2

What did SCOHIA report in animals?

SCOHIA reported numerically greater weight loss than retatrutide at equal molar doses in obese rats. Separate primate exposure findings suggested potential for a weekly formulation. Neither experiment establishes a human regimen. 1

An equal-molar comparison matches the amount of molecules administered. It does not necessarily match receptor activity, exposure or tolerability. For interpretation, the key questions are how the comparison was designed and whether the results remain meaningful across doses and experimental conditions.

Can the study establish better muscle preservation?

The sponsor reports proportionally less lean-body-mass loss in rats. That does not establish human muscle strength or physical function. Those outcomes require their own measurements; body-composition findings should not silently replace them. 1

The source material available for this summary did not include a complete experimental poster or independent replication. Without that detail, it would be premature to turn the announcement into a numerical ranking of medicines. Readers should keep animal body-composition findings separate from patient outcomes.

What is the planned US FDA step?

Celltrion targets a February 2027 US Investigational New Drug submission and first patient dosing in the second quarter, according to SCOHIA. Both dates are plans. 1

FDA explains that an IND supports the move into investigational human studies. It includes nonclinical pharmacology and toxicology, manufacturing information and proposed clinical protocols. The purpose includes assessing whether initial testing would expose participants to unreasonable risk; it is not the same as permission to market an approved medicine. 3

What evidence would make a later update more useful?

The next meaningful evidence would include a verifiable human-study record, the actual enrolled population, safety observations and results tied to a defined comparator. Filing, trial initiation, completion and approval should each be reported on their own dates. A forecast should remain labeled as a forecast until confirmed. 3

The announcement comes from TIDES Europe, with US development still planned. A mechanism comparison should retain those geographical and evidence-stage distinctions. 1 2

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.